CYCC - Rasio cepet Cyclacel Pharmaceuticals

The current price chart for Cyclacel Pharmaceuticals (CYCC) helps assess the company's approach to recruiting scientists by providing creative independence and long-term incentives. Meanwhile, the current separate_ratio_quick stands at 5.70, a critical factor to consider as the startup has no sales and is increasing laboratory expenditures. The business strategy relies on developing treatments for solid tumors and leukemia to diversify risks.

The quick ratio assesses a company's ability to instantaneously settle short-term obligations, excluding low-liquidity inventories. By analyzing the quick liquidity vector, an investor gains visibility into the actual volume of cash and accounts receivable relative to debt. For Cyclacel Pharmaceuticals (CYCC), which does not operate large-scale factories, this metric is critical as it reflects financial stability while conducting costly oncology research. Effective capital management here minimizes default risk in the absence of inventory holdings.